pISSN 1226-6051
eISSN 2508-786X

Table. 5.

Table. 5.

Prescription status of tablet splitting based on NIOSH-hazardous drugs list in 2016

API name (Strength)Prescription portion including splitted tablet % (N*)Therapeutic classLow dose
Group 1: Antineoplastic drugs, including those with the manufacturer’s safe-handling guidance
 Methotrexate (2.5 mg)1.5 (259/17,672)Anticancer drug-
 Mercaptopurine (50 mg)52.3 (113/216)Anticancer drug-
 Cyclophosphamide (50 mg)25.1 (59/235)Anticancer drug-
 Capecitabine (500 mg)1.1 (18/1,608)Anticancer drug-
 Sorafenib tosylate (200 mg)1.8 (6/325)Anticancer drug-

Group 2: Non-antineoplastic drugs that meet one or more of the NIOSH criteria for a hazardous drug, including those with the manufacturer’s safe-handling guidance
 Spironolactone (25 mg)43.1 (15,242/35,363)Diuretic drug-
 Methimazole (5 mg)32.7 (6,716/20,530)Thyroid, Parathyroid hormone drug-
 Risperidone (1 mg)44.3 (2,149/4,847)Psychotropic drug-
 Spironolactone (50 mg)68.2 (2,068/3,031)Diuretic drug25 mg
 Propylthiouracil (50 mg)15.7 (1,089/6,950) >Thyroid, Parathyroid hormone drug-

Group 3: Non-antineoplastic drugs that primarily have adverse reproductive effects
 Clonazepam (0.5 mg)43.0 (13,987/32,540)Anticonvulsant drug-
 Warfarin sodium (2 mg)49.2 (7,545/15,341)Anticoagulant drug-
 Warfarin sodium (5 mg)63.0 (5,021/7,964)Anticoagulant drug2 mg
 Paroxetine hydrochloride (20 mg)41.5 (1,732/4,170)Psychotropic drug10, 12.5 mg
 Colchicine (600 μg)4.7 (1,500/32,182)Arthrifuge drug-

Total number of prescriptions of each API

Korean J Clin Pharm 2019;29:231-7 https://doi.org/10.24304/kjcp.2019.29.4.231
© 2019 Korean J Clin Pharm